Modulation of CNS signal transduction pathways gene expression by mood- stabilizing agents: Therapeutic implications

Journal of Clinical Psychiatry

Volumn 60, Issue SUPPL. 2, 1999, Pages 27-41

  Manji, Husseini K ^a   Bebchuk, Joseph M ^a   Moore, Gregory J ^a   Glitz, Debra ^a   Hasanat, Khondakar A ^a   Chen, Guang ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; LITHIUM; MEVINOLIN; TAMOXIFEN; TAMOXIFEN CITRATE; VALPROATE SEMISODIUM; VALPROIC ACID;

AFFECTIVE NEUROSIS; CONFERENCE PAPER; DRUG TARGETING; ENZYME INHIBITION; HUMAN; NERVE CELL EXCITABILITY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

BIPOLAR DISORDER; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CARBAMAZEPINE; GENE EXPRESSION; GLYCOGEN SYNTHASE KINASES; HUMANS; LITHIUM; MOOD DISORDERS; PROTEIN KINASE C; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TAMOXIFEN; TRANSCRIPTION FACTOR AP-1; VALPROIC ACID;

EID: 0033035485     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (138)

1. Goodwin FK, Jamison KR. Manic-Depressive Illness. New York, NY: Oxford University Press; 1990
2. Simpson SG, Jamison KR. The risk of suicide in patients with bipolar disorders. J Clin Psychiatry 1999;60(suppl 2):53-56
3. Greenberg PE, Stiglin LE, Finkelstein SN, et al. The economic burden of depression in 1990. J Clin Psychiatry 1993;54:405-419
4. Wyatt RJ, Henter I. An economic evaluation of manic-depressive illness. Soc Psychiatry Psychiatr Epidemiol 1995:30:213-219
5. Baldessarini RJ, Tondo L. Effects of lithium treatment and its discontinuation in bipolar disorder: overview of recent research findings from the International Consortium for Bipolar Disorders Research. American Society of Clinical Psychopharmacology Progress Notes, Fall 1997;8(2):21-26
6. Manji HK, Lenox RH. Lithium: a unique cation in biology and medicine. Neuropsychopharmacology 1998;19:161-240
7. Baldessarini RJ, Tondo L, Hennen J. Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders. J Clin Psychiatry 1999;60(suppl 2):77-84
8. Müller-Oerlinghausen B, Ahrens B, Grof E, et al. The effect of long-term lithium treatment on the mortality of patients with manic-depressive and schizoaffective illness. Acta Psychiatr Scand 1992;86:218-222
9. Bunney WE, Garland-Bunney BL. Mechanisms of action of lithium in affective illness: basic and clinical implications. In: Meltzer HY, ed. Psychopharmacology: The Third Generation of Progress. New York, NY: Raven Press; 1987:553-565
10. Manji HK, Potter WZ, Lenox RH. Signal transduction pathways: molecular targets for lithium's actions. Arch Gen Psychiatry 1995;52:531-543
11. Kramlinger KG, Post RM. The addition of lithium to carbamazepine: anti-depressant efficacy in treatment-resistent mania. Arch Gen Psychiatry 1989;46:794-800
12. Chou JC. Recent advances in treatment of acute mania. J Clin Psychopharmacol 1991;11(1):3-21
13. Post RM, Ballenger JC, Uhde TW, et al. Efficacy of carbamazepine in manic-depressive illness: implications for underlying mechanisms. In: Post RM, Ballenger JC. eds. Neurobiology of Mood Disorders. Baltimore, Md: Williams & Wilkins; 1984:777-816
14. McElroy SL, Keck PE Jr, Pope HG Jr, et al. Valproate in the treatment of bipolar disorder: literature review and clinical guidelines. J Clin Psychopharmacol 1992;12:42S-52S
15. Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA 1994;271:918-924
16. Swann AC, Bowden CL, Morris D, et al. Depression during mania: treatment response to lithium or divalproex. Arch Gen Psychiatry 1997;54: 37-42
17. Keck PE, McElroy SL. Outcome in the pharmacologic treatment of bipolar disorder. J Clin Psychopharmacol 1996;16(suppl 1):15S-23S
18. Bowden CL. Lithium comparison to valproate and carbamazepine. Presented at the 20th Congress of the Collegium Internationale Neuropsychopharmacologicum; June 23-27, 1996; Melbourne, Australia
19. Post RM, Weiss SR, Clark M, et al. Lithium, carbamazepine and valproate in affective illness: biochemical and neurobiological mechanisms. In: Manji HK, Bowden CL, Belmaker RH, eds. Mechanisms of Antibipolar Treatments. American Psychiatric Press. In press
20. Manji HK, Chen G, Hsiao JK, et al. Regulation of signal transduction pathways by mood stabilizing agents: implications for the pathophysiology and treatment of bipolar affective disorder. In: Manji HK, Bowden CL, Belmaker RH, eds. Mechanisms of Antibipolar Treatments. American Psychiatric Press. In press
21. Lenox RH, Manji HK. Lithium. In: Nemeroff CB, Schatzberg AF, eds. American Psychiatric Press Textbook of Psychopharmacology. Washington, DC: American Psychiatric Press: 1995:303-350
22. Post RM, Weiss SR, Chuang DM. Mechanisms of action of anti-convulsants in affective disorders: comparisons with lithium. J Clin Psychopharmacol 1992;12:42S-52S
23. Rogawski MA, Porter RJ. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising development stage compounds. Pharmacol Rev 1990;42:223-286
24. Manji HK. G proteins: implications for psychiatry. Am J Psychiatry 1992; 149:746-760
25. Bourne HR, Nicoll R. Molecular machines integrate coincident synaptic signals. Cell 1993;72(suppl):65-75
26. Ross EM. Signal sorting and amplification through G protein-coupled receptors. Neuron 1989;3:141-152
27. Taylor CW. The role of G proteins in transmembrane signaling. Biochem J 1990;272:1-13
28. Jope RS, Williams MB. Lithium and brain signal transduction systems. Biochem Pharmacol 1994;77:429-441
29. Baraban JM, Worley PF, Synder SH. Second messenger systems and psychoactive drug action: focus on the phosphoinositide system and lithium. Am J Psychiatry 1989;146:1251-1260
30. Chuang DM. Neurotransmitter receptors and phosphoinositide turnover. Annu Rev Pharmacol Toxicol 1989;29:71-110
31. Catt KJ, Balla T. Phosphoinositide metabolism and hormone action. Annu Rev Med 1989;40:487-509
32. Berridge MJ, Irvine RF. Inositol phosphates and cell signalling. Nature 1989;341:197-205
33. Rana RS, Hokin LE. Role of phosphoinositides in transmembrane signaling. Physiol Rev 1990;70:115-164
34. Fisher SK, Heacock AM, Agranoff BW. Inositol lipids and signal transduction in the nervous system: an update. J Neurochem 1992;58:18-38
35. Allison JH, Stewart MA. Reduced brain inositol in lithium treated rats. Nature [New Biol] 1971;233:267-268
36. Hallcher LM, Sherman WR. The effects of lithium ion and other agents on the activity of myo-mositol-1-phosphatase from bovine brain. J Biol Chem 1980;255:10896-10901
37. Nahorski SR, Ragan CI, Challiss RAJ. Lithium and the phosphoinositide cycle: an example of uncompetitive inhibition and its pharmacological consequences. Trends Pharmacol Sci 1991;12:297-303
38. Nahorski SR, Jenkinson S, Challiss RA. Disruption of phosphoinositide signalling by lithium. Biochem Soc Trans 1992;20:430-134
39. Berridge MJ, Downes CP, Hanley MR. Lithium amplifies agonist-dependent phosphatidylinositol responses in brain and salivary glands. Biochem J 1982;206:587-595
40. Berridge MJ, Downes CP, Hanley MR. Neural and developmental actions of lithium: a unifying hypothesis. Cell 1989;59:411-419
41. Sherman WR. Lithium and the phosphoinositide signalling system. In: Birch NJ, ed. Lithium and the Cell. London, England: Academic Press: 1991:121-157
42. Nishizuka Y. Protein kinase C and lipid signalling for sustained cellular responses. FASEB J 1995;9:484-496
43. Godfrey PP, McClue SJ, White AM, et al. Potentiation by lithium of CMP-phosphatidate formation in carbachol-stimulated rat cerebral-cortical slices and its reversal by myo-inositol. Biochem J 1989;258:621-624
44. Pontzer NJ, Crews FT. Desensitization of muscarinic stimulated hippocampal cell firing is related to phosphoinositide hydrolysis and inhibited by lithium. J Pharmacol Exp Ther 1990;253:921-929
45. Kofman O, Belmaker RH. Intracerebroventricular myo-inositol antagonizes lithium-induced suppression of rearing behaviour in rats. Brain Res 1990;534:345-347
46. Kofman O, Belmaker RH. Biochemical, behavioral and clinical studies of the role of inositol in lithium treatment and depression. Biol Psychiatry 1993;34:839-852
47. Tricklebank MD, Singh L, Jackson A, et al. Evidence that a proconvulsant action of lithium is mediated by inhibition of myo-inositol phosphatase in mouse brain. Brain Res 1991;558:145-148
48. Manji HK, Bersudsky Y, Chen G, et al. Modulation of PKC isozymes and substrates by lithium: the role of myo-inositol. Neuropsychopharmacology 1996;15:370-382
49. Faedda GL, Baldessarini RJ, Tohen M, et al. Episode sequence in bipolar disorder and response to lithium treatment. Am J Psychiatry 1991;148: 1237-1239
50. Goodnick PJ, Fieve RR, Peselow E, et al. General behavior inventory: measurement of subclinical changes during depression and lithium prophylaxis. Acta Psychiatr Scand 1986;73:529-532
51. Himmelhoch JM, Garfinkel ME. Mixed mania: diagnosis and treatment. Psychopharmacol Bull 1986;22:613-620
52. Swann AC, Secunda SK, Katz MM. et al. Lithium treatment of mania: clinical characteristics, specificity of symptom change, and outcome. Psychiatry Res 1986;18:127-141
53. Gurling H, Smyth C. Kalsi G, et al. Linkage findings in bipolar disorder. Nature Genet 1995;10:8-9
54. Gelernter J. Genetics of bipolar affective disorder: time for another reinvention? Am J Hum Genet 1995;56(6):1262-1266
55. Berrettini W, Ferraro T. Choi H, et al. Linkage studies of bipolar illness. Arch Gen Psychiatry 1997;54:32-39
56. Nurnberger JI Jr, Berrettini W. Psychiatric Genetics. London, England: Chapman & Hall: 1997
57. Davies JL, Kawaguchi Y, Bennett ST, et al. A genome-wide search for human type 1 diabetes susceptibility genes. Nature 1994;371(6493):130-136
58. Aitman TJ, Todd JA. Molecular genetics of diabetes mellitus. Baillieres Clin Endocrinol Metab 1995;9(3):631-656
59. Thibonnier M. Schork NJ. The genetics of hypertension. Curr Opin Genet Dev 1995;5:362-370
60. O'Connor DT, Kailasam MT, Parmer RJ. Complex trait genetics: new methods yield a result for essential hypertension. J Clin Invest 1996;97: 1997-1998
61. Philibert RA, Egeland JA. Paul SM, et al. The inheritance of bipolar affective disorder: abundant genes coming together. J Affect Disord 1997:43(1): 1-3
62. Blackwood DHR, He L, Morris SW, et al. A locus for bipolar affective disorder on chromosome 4p. Nature Genet 1996;12:427-430
63. Ginns EI, Ott J, Egeland JA, et al. A genome-wide search for chromosomal loci linked to bipolar affective disorder in the Old Order Amish. Nature Genet 1996;12:431-435
64. Freimer NB, Reus VI, Escamilla MA, et al. Genetic mapping using haplo-type, association and linkage methods suggests a locus for severe bipolar disorder (BPI) at 18q22-q23. Nature Genet 1996;12:436-441
65. Risch N, Botstein D. A manic depressive history [news]. Nature Genet 1996;12:351-353
66. Steen VM, Gulbrandsen AK, Eiken HG, et al. Lack of genetic variation in the coding region of the myo-inositol monophosphatase gene in lithium-treated patients with manic depressive illness. Pharmacogenetics 1996;6 (1):113-116
67. Sjoholt G, Molven A, Lovlie R, et al. Genomic structure and chromosomal localization of a human myo-inositol monophosphatase gene (IMPA). Genomics 1997;45(1):113-122
68. van den Boogaart A, Ala-Korpela M, Jokisaari J, et al. Time and frequency domain analysis of NMR data compared: an application to 1D 1H spectra of lipoproteins. Magn Reson Med 1994;31:347-358
69. deBeer R, van den Boogaart A, van Ormondt D, et al. Application of time-domain fitting in the quantification of in vivo 1H spectroscopic imaging data sets. NMR Biomed 1992;5(4):171-178
70. Moore GJ, Bebchuk JM, Parrish JK, et al. Lithium induced neurochemical changes in bipolar disorder: in vivo investigation of the inositol depletion hypothesis. In: Proceedings of the International Society of Magnetic Resonance in Medicine; April 18-24, 1998; Sydney, Australia. Page 504
71. Stabel S, Parker PJ. Protein kinase C. Pharmacol Ther 1991;51:71-95
72. Huang KP. The mechanism of protein kinase C activation. Trends Neurosci 1989;12:425-432
73. Manji HK, Chen G, Hsiao JK, et al. Regulation of signal transduction pathways by mood-stabilizing agents: implications for the delayed onset of therapeutic efficacy. J Clin Psychiatry 1996;57(suppl 13):34-46
74. Wang HY, Friedman E. Lithium inhibition of protein kinase C activation-induced serotonin release. Psychopharmacology (Berl) 1989;99:213-218
75. DeGrann PN, Schrama LH, Heemskerk FM, et al. The role of protein kinase C substrate B-50 (GAP-43) in neurotransmitter release and long-term potentiation. Adv Exp Med Biol 1990;268:347-358
76. Robinson PJ. The role of protein kinase C and its neuronal substrates dephosphin. B-50, and MARCKS in neurotransmitter release. Mol Neurobiol 1991;5:87-130
77. Lenox RH, Watson DG. Patel J, et al. Chronic lithium administration alters a prominent PKC substrate in rat hippocampus. Brain Res 1992;570: 333-340
78. Manji HK, Etcheberrigaray R, Chen G, et al. Lithium dramatically decreases membrane-associated PKC in the hippocampus: selectivity for the alpha isozyme. J Neurochem 1993;61:2303-2310
79. Chen G, Manji HK, Hawver DB, et al. Chronic sodium valproate selectively decreases protein kinase C α and ε in vitro. J Neurochem 1994;63: 2361-2364
80. Conn PJ, Sweatt JD. Protein kinase C in the nervous system. In: Kuo JF, ed. Protein Kinase C. New York, NY: Oxford University Press; 1994:199-235
81. Manji HK, Potter WZ. Emerging strategies in affective disorders. In: Pullan L, Patel J, eds. Emerging Strategies in Neurotherapeutics. Totowa, NJ: Humana Press; 1995:35-83
82. Jordan VC. A current view of tamoxifen for the treatment of breast cancer. Br J Pharmacol 1994;110:507-517
83. Catherino WH, Jordan VC. A risk-benefit assessment of tamoxifen therapy. Drug Saf 1993;8:381-397
84. Couldwell WT, Weiss MH, DeGiorgio CM, et al. Clinical and radiographic response in patients with recurrent malignant gliomas treated with high-dose tamoxifen. Neurosurgery 1993;32:485-489
85. Bebchuk JM, Arfken CL, Dolan-Manji S, et al. A preliminary investigation of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania. Arch Gen Psychiatry. In press
86. Freidman E, Hoau YW, Levinson D, et al. Altered platelet protein kinase C activity in bipolar affective disorder, manic episode. Biol Psychiatry 1993;33:520-525
87. Wang HY, Friedman E. Enhanced protein kinase C activity and translocation in bipolar affective disorder brains. Biol Psychiatry 1996;40: 568-575
88. Mork A, Geisler A, Hollund P. Effects of lithium on second messenger systems in the brain. Pharmacol Toxicol 1992;71(suppl 1):4-17
89. Risby ED, Hsiao JK, Manji HK, et al. The mechanisms of action of lithium. Arch Gen Psychiatry 1991;48:513-524
90. Ui M. Pertussis toxin as a valuable probe for G protein involvement in signal transduction. In: Moss J, Vaughn M, eds. ADP-Ribosylation Toxins and G Proteins. Washington, DC: American Society for Microbiology; 1990
91. 1 in humans. Life Sci 1992;50:227-233
92. 1 modulation of adenylate cyclase in brain. J Neurochem 1992; 59:200-205
93. Mann JJ, Oquendo M. Underwood MD. et al. The neurobiology of suicide risk: a review for the clinician. J Clin Psychiatry 1999;60(suppl 2): 7-11
94. Manji HK, Hsiao JK, Risby ED, et al. The mechanisms of action of lithium. Arch Gen Psychiatry 1991;48:505-512
95. Kaplan JR, Muldoon MF, Manuck SB, et al. Assessing the observed relationship between low cholesterol and violence-related mortality: implications for suicide risk. Ann N Y Acad Sci 1997;836:57-80
96. Maltese WA. Postranslational modification of proteins by isoprenoids in mammalian cells. FASEB J 1990;4:3319-3328
97. Casey PJ. Mechanisms of protein prenylation and role in G protein function. Biochem Soc Trans 1995;23:161-166
98. Goldstein LG, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425-430
99. Helper JR, Gilman AG. G proteins. Trends Biochem Sci 1992;17: 383-387
100. s in intact cells alters its abundance, rate of degradation, and membrane activity. J Cell Biol 1992;119:1297-1307
101. Wedegaertner PB, Wilson PT, Bourne HR. Lipid modifications of trimeric G proteins. J Biol Chem 1995;270:503-506
102. Iniguez-Lluhi JA, Simon MI, Robishaw JD, et al. G protein βγ subunits synthesized in Sf9 cells. J Biol Chem 1992;267:23409-23417
103. Repko EM, Maltese WA. Post-translational isoprenylation of cellular proteins is altered in response to mevalonate availability. J Biol Chem 1989;264:9945-9952
104. Chiloeches A, Lasa M, Brihuega F, et al. Effects of lovastatin on adenylyl cyclase activity and G proteins in GH4Cl cells. FEBS Lett 1995;361: 46-50
105. Lasa M, Chiloeches A, Garcia N, et al. Lovastatin decreases prolactin and growth hormone gene expression in GH4Cl cells through a cAMP dependent mechanism. Mol Cell Endocrinol 1997;130:93-100
106. Kreuzer J, Schmidts A, Marquetant R, et al. Protein kinase C activation after cellular adhesion on fibronectin: partial suppression after inhibition of protein isoprenylation. Eur J Med Res 1997;2:305-310
107. Purpura DP, Shofer RJ. Excitatory action of dibutyryl cyclic adenosine monophosphate on immature cerebral cortex. Brain Res 1972;38: 179-181
108. Gessa GA, Krishna G, Forn J, et al. Behavioral and vegetative effects produced by dibutyryl cyclic AMP injected into different areas of the brain. In: Greengard P. Costa E, eds. Advances in Biochemical Psychopharmacology. vol 3. New York, NY: Raven Press; 1970:371-381
109. Kuriyama K, Kakita K. Cholera toxin induced epileptogenic focus: an animal model for studying roles of cyclic AMP in the establishment of epilepsy. In: Battistin L, ed. Neurochemistry and Clinical Neurology. New York, NY: Alan R Liss; 1980:141-155
110. Ludvig N, Moshe SL. Different behavioral and electrographic effects of acoustic stimulation and dibutyryl cyclic AMP injection into the inferior colliculus in normal and in genetically epilepsy-prone rats. Epilepsy Res 1989;3:185-190
111. Ludvig N, Miscara PK, Yan QS, et al. The combined EEG-intracerebral microdialysis technique: a new tool for neuropharmacological studies on freely behaving animals, J Neurosci Lett 1992;43:129-137
112. Hudson CJ, Young LT, Li PP, et al. CNS signal transduction in the pathophysiology and pharmacotherapy of affective disorders and schizophrenia. Synapse 1993;13:278-293
113. Chen G, Hawver D, Wright C, et al. Attenuation of adenylyl cyclases by carbamazepine in vitro. J Neurochem 1996;67:2079-2086
114. Hyman SE, Nestler EJ. Initiation and adaptation: a paradigm for understanding psychotropic drug action. Am J Psychiatry 1996;153:151-162
115. Karin M, Smeal T. Control of transcription factors by signal transduction pathways: the beginning of the end. Trends Biochem Sci 1992;17: 418-422
116. Hughes P, Dragunow M. Induction of immediate-early genes and the control of neurotransmitter-regulated gene expression within the nervous system. Pharmacol Rev 1995;47:133-178
117. Jope RS. Song L. AP-I and NF-κB stimulated by carbachol in human neuroblastoma SH-SY5Y cells are differentially sensitive to inhibition by lithium. Mol Brain Res 1997;50:171-180
118. Ozaki N, Chuang DM. Lithium increases transcription factor binding to AP-1 and cyclic AMP-responsive element in cultured neurons and rat brain. J Neurochem 1997;69:2336-2344
119. Unlap MT, Jope RS. Lithium attenuates nerve growth factor-induced activation of AP-1 DNA binding activity in PC12 cells. Neuropsychopharmacology 1997;17(1):12-17
120. Williams MB, Jope RS. Circadian variation in rat brain AP-1 DNA binding activity after cholinergic stimulation: modulation by lithium. Psychopharmacology (Berl) 1995;122(4):363-368
121. Yuan PX, Chen G, Manji HK. Concordant regulation of gene expression by lithium and valproic acid in vitro. In: Abstracts of the 26th Annual Meeting of the Society of Neuroscience; November 16-21, 1996; Washington, DC
122. Chen G, Yuan PX, Hawver DB, et al. Increase in AP-1 transcription factor DNA binding activity by valproic acid. Neuropsychopharmacology 1997; 16:238-245
123. Chen G, Yuan PX, Manji HK. Regulation of transcription factor DNA binding activity by mood stabilizing agents. Presented at the 36th annual meeting of the American College of Neuropsychopharmacology: December 8-12, 1997; Kamuela, Hawaii
124. Ozaki N, Chuang D-M. Effect of lithium on transcription factor binding in cultured cerebellar granule cells and the brain of rats. J Neurochem 1997;69:2336-2344
125. Yuan PX, Chen G, Huang LD, et al. Lithium stimulates gene expression through the AP-1 transcription factor pathway. Mol Brain Res 1998;5819: 225-230
126. Kumer SC, Vrana KE. Intricate regulation of tyrosine hydroxylase activity and gene expression. J Neurochem 1996;67:443-461
127. Drevets WC, Videen TO, Price JL, et al. A functional anatomical study of unipolar depression. J Neurosci 1992;12:3628-3641
128. Drevets WC, Price JL, Simpson JR Jr, et al. Subgenual prefrontal cortex abnormalities in mood disorders. Nature 1997;386:824-827
129. Soares JC, Mann JJ. The functional neuroanatomy of mood disorders. J Psychiatr Res 1997;1:393-432
130. Ketter TA, George MS, Kimbrell TA, et al. Neuroanatomical models and brain imaging studies. In: Joffe RT, Young LT, eds. Bipolar Disorder: Biological Models and Their Clinical Application. New York, NY: Marcel Dekker: 1997:179-217
131. Chen G, Yuan PX, Jiang Y, et al. Lithium increases tyrosine hydroxylase levels both in vivo and in vitro. J Neurochem 1998;90:1768-1771
132. Manji HK, Potter WZ. Monoaminergic mechanisms. In: Joffe RT, Young LT, eds. Bipolar Disorder: Biological Models and Their Clinical Application. New York, NY: Marcel Dekker; 1997:1-40
133. Boyle WJ, Smeal T, Defize LH. et al. Activation of protein kinase C decreases phosphorylation of c-Jun at sites that negatively regulate its DNA-binding activity. Cell 1991;64:573-584
134. Lin A, Smeal T, Binetruy B, et al. Control of AP-1 activity by signal transduction cascades. Adv Second Messenger Phosphoprotein Res 1993;28: 255-260
135. Hedgepeth CM, Conrad LJ, Zhang J, et al. Activation of the Wnt signaling pathway: a molecular mechanism for lithium action. Dev Biol 1997; 185:82-91
136. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci 1996;93:8455-8459
137. Stambolic V, Ruel L, Laurent R, et al. Lithium inhibits glycogen symhase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 1996;6:1664-1668
138. Chen G, Manji HK. Inhibition of glycogen synthase kinase-3 by the anti-convulsant and anti manic agent valproic acid. Presented at the 27th annual meeting of the Society for Neuroscience; October 25-30, 1997; New Orleans, La